OraSure Technologies (NASDAQ:OSUR) Issues Quarterly Earnings Results, Misses Expectations By $0.14 EPS

OraSure Technologies (NASDAQ:OSURGet Rating) released its quarterly earnings results on Tuesday. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.14), MarketWatch Earnings reports. OraSure Technologies had a negative return on equity of 5.83% and a negative net margin of 9.84%. The firm had revenue of $67.71 million for the quarter, compared to the consensus estimate of $60.17 million. During the same quarter in the previous year, the business posted $0.05 EPS. The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year.

Shares of NASDAQ:OSUR opened at $5.27 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.46 and a current ratio of 4.24. OraSure Technologies has a 52-week low of $5.19 and a 52-week high of $13.57. The business’s 50 day simple moving average is $6.75 and its two-hundred day simple moving average is $8.24. The firm has a market cap of $389.54 million, a P/E ratio of -16.47 and a beta of -0.26.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Swiss National Bank lifted its holdings in shares of OraSure Technologies by 7.7% in the 1st quarter. Swiss National Bank now owns 170,300 shares of the medical instruments supplier’s stock worth $1,155,000 after purchasing an additional 12,200 shares in the last quarter. Advisor Group Holdings Inc. raised its holdings in OraSure Technologies by 12.0% during the first quarter. Advisor Group Holdings Inc. now owns 20,720 shares of the medical instruments supplier’s stock worth $163,000 after buying an additional 2,225 shares during the last quarter. Barclays PLC lifted its stake in shares of OraSure Technologies by 39.3% in the fourth quarter. Barclays PLC now owns 93,474 shares of the medical instruments supplier’s stock valued at $813,000 after buying an additional 26,348 shares in the last quarter. BlackRock Inc. grew its holdings in shares of OraSure Technologies by 1.2% during the fourth quarter. BlackRock Inc. now owns 13,893,887 shares of the medical instruments supplier’s stock valued at $120,737,000 after buying an additional 160,933 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of OraSure Technologies by 21.2% during the fourth quarter. Deutsche Bank AG now owns 300,197 shares of the medical instruments supplier’s stock valued at $2,609,000 after buying an additional 52,555 shares during the last quarter. Hedge funds and other institutional investors own 97.00% of the company’s stock.

A number of brokerages recently weighed in on OSUR. Citigroup lowered their target price on shares of OraSure Technologies from $12.00 to $10.00 in a research note on Wednesday. Zacks Investment Research raised OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, March 1st. TheStreet cut OraSure Technologies from a “c-” rating to a “d+” rating in a research note on Friday, March 4th. Finally, StockNews.com upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a report on Friday, April 29th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $12.17.

About OraSure Technologies (Get Rating)

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Featured Stories

Earnings History for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.